March 10 (Reuters) - 4D Molecular Therapeutics Inc FDMT.O:
4DMT ANNOUNCES FIRST PATIENTS ENROLLED IN 4FRONT-1 PHASE 3 CLINICAL TRIAL EVALUATING 4D-150 IN WET AMD
4D MOLECULAR THERAPEUTICS INC - 4FRONT-2 TRIAL EXPECTED TO INITIATE IN Q3 2025
Source text: nGNX9DC81n
Further company coverage: FDMT.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.